–
June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workforce. Orphazyme remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. following receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on June 17, 2021.
Orphazyme CEO Christophe Bourdon said: “
As a result of the restructuring
of the company
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Orphazyme announces restructuring to focus resources on supporting a path forward for .
ORPHAZYME A/SJune 28, 2021 GMT
Orphazyme A/S
-
Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workforce. Orphazyme remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. following receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on June 17, 2021.
FDA rejection of rare disease drug leads Orphazyme to cut two thirds of staff medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.